Investors Urged to Join Class Action Against Regeneron Pharmaceuticals by March 10, 2025

Investors Rally for Class Action Against Regeneron Pharmaceuticals

Overview
In a recent announcement, Levi & Korsinsky, LLP has urged investors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to join a class action lawsuit. This lawsuit seeks to recover financial losses incurred by investors due to alleged securities fraud between November 2, 2023, and October 30, 2024. If you fall within this timeline and have experienced a loss, the deadline to apply for lead plaintiff status is March 10, 2025.

Details of the Allegations
The complaints against Regeneron revolve around several assertions that the company allegedly misled investors by making false statements regarding its pricing and sales practices related to its primary product, Eylea. The lawsuit outlines that Regeneron purportedly compensated distributors for credit card fees, which should have been disclosed as price concessions but were not. As a result, the company overstated its Average Selling Price (ASP) reported to government agencies, breaching the False Claims Act.

Impacts on Investors
Investors who purchased shares during the specified timeframe and suffered losses are encouraged to take action before the deadline. Levi & Korsinsky has a proven track record of advocating for shareholders, claiming to have secured hundreds of millions of dollars in similar cases in the past two decades. Notably, they have been recognized multiple times as one of the leading securities litigation firms in the United States by ISS Securities Class Action Services.

Next Steps for Affected Investors
If you are a Regeneron investor and believe you may have a case, you can reach out to Levi & Korsinsky or fill out the submission form available through their website to gain further insight. Notably, participation in the class action is at no cost to the investors, eliminating the worry of upfront legal fees or financial obligations.

Contact Information
You can get in touch with Levi & Korsinsky by reaching out to Joseph E. Levi, Esq. at (212) 363-7500, or via email. Their office is located at 33 Whitehall Street, 17th Floor, New York, NY 10004, and they are committed to providing the necessary support for affected shareholders.

Conclusion

As allegations of misleading practices unfold regarding Regeneron Pharmaceuticals, investors are encouraged to act promptly if they have been affected. Joining this class action suit not only offers a potential path for recovery but also strengthens the accountability in companies' financial reporting and practices, which is vital in a robust investment environment.